Genetic variations in the β2M/HLA-E immunomodulatory complex to predict outcomes in metastatic colorectal cancer (mCRC) patients (pts) treated with first line FOLFIRI/Cetuximab: Data from the phase III FIRE-3 trial

被引：0
|
作者：
Naseem, Madiha
Stintzing, Sebastian
Cao, Shu
Puccini, Alberto
Tokunaga, Ryuma
Battaglin, Francesca
Barzi, Afsaneh
Berger, Martin D.
Soni, Shivani
McSkane, Michelle
Zhang, Wu
Millstein, Joshua
Heinemann, Volker
Lenz, Heinz-Josef
机构：
[1] USC Norris Comprehens Canc Ctr, Keck Sch Med, Div Med Oncol, Los Angeles, CA USA
[2] Ludwig Maximilian Univ Munich, Munich, Germany
[3] USC Norris Comprehens Canc Ctr, Keck Sch Med, Dept Prevent Med, Los Angeles, CA USA
[4] Veneto Inst Oncol IOV IRCCS, Med Oncol Unit 1, Clin & Expt Oncol Dept, Padua, Italy
[5] USC Keck Sch Med, Norris Comprehens Canc Ctr, Los Angeles, CA USA
[6] USC Keck Sch Med, Los Angeles, CA USA
[7] Ludwig Maximilians Univ Munchen, Univ Hosp Munich, Munich, Germany
[8] Univ Southern Calif, Los Angeles, CA 90007 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.12107
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
12107
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Variation in genetic polymorphisms and gene expression of HLA-E to predict outcomes in metastatic colorectal cancer (mCRC) patients (pts) treated with first-line FOLFIRI/cetuximab: Data from the phase III FIRE-3 trial
    Naseem, Madiha
    Cao, Shu
    Stintzing, Sebastian
    Battaglin, Francesca
    Tokunaga, Ryuma
    Puccini, Alberto
    Berger, Martin D.
    Soni, Shivani
    Zhang, Wu
    Barzi, Afsaneh
    Heinemann, Volker
    Lenz, Heinz-Josef
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [2] Genetic variations within the HER3 gene predict outcome for mCRC patients treated with first-line FOLFIRI/bevacizumab or FOLFIRI/cetuximab: Data from FIRE-3
    Berger, M. D.
    Stintzing, S.
    Heinemann, V.
    Cao, S.
    Yang, D.
    Miyamoto, Y.
    Suenaga, M.
    Hanna, D. L.
    Soni, S.
    Puccini, A.
    Tokunaga, R.
    Naseem, M.
    Battaglin, F.
    McSkane, M.
    Zhang, W.
    Lenz, H-J.
    [J]. ANNALS OF ONCOLOGY, 2018, 29
  • [3] Polymorphisms in the telomerase complex to predict outcome in patients (pts) with metastatic colorectal cancer (mCRC): Data from TRIBE and FIRE-3 phase III trials
    Battaglin, Francesca
    Loupakis, Fotios
    Stintzing, Sebastian
    Cao, Shu
    Puccini, Alberto
    Tokunaga, Ryuma
    Naseem, Madiha
    Berger, Martin D.
    Soni, Shivani
    Lo, Jae Ho
    Bergamo, Francesca
    Lonardi, Sara
    Millstein, Joshua
    Zhang, Wu
    Zagonel, Vittorina
    Cremolini, Chiara
    Falcone, Alfredo
    Heinemann, Volker
    Lenz, Heinz-Josef
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [4] Genetic variants in the lipopolysaccharide (LPS) receptor complex and TLR4 expression levels to predict efficacy of cetuximab (cet) in patients (pts) with metastatic colorectal cancer (mCRC): Data from the FIRE-3 phase III trial
    Battaglin, Francesca
    Puccini, Alberto
    Cao, Shu
    Millstein, Joshua
    Tokunaga, Ryuma
    Naseem, Madiha
    Soni, Shivani
    Lo, Jae Ho
    Ning, Tricia
    Arai, Hiroyuki
    Berger, Martin D.
    Barzi, Afsaneh
    Zhang, Wu
    Heinemann, Volker
    Stintzing, Sebastian
    Lenz, Heinz-Josef
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [5] Genetic variants in methylation and demethylation pathways to predict clinical outcome in metastatic colorectal cancer (mCRC) patients (pts) treated with first-line FOLFIRI/Bev: Data from TRIBE and FIRE-3 trials.
    Puccini, Alberto
    Loupakis, Fotios
    Stintzing, Sebastian
    Berger, Martin D.
    Tokunaga, Ryuma
    Naseem, Madiha
    Battaglin, Francesca
    Cao, Shu
    Millstein, Joshua
    Soni, Shivani
    McSkane, Michelle
    Zhang, Wu
    Heinemann, Volker
    Falcone, Alfredo
    Lenz, Heinz-Josef
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [6] Genetic variations within the vitamin C transporter genes to predict outcome in metastatic colorectal cancer patients treated with first-line FOLFIRI and bevacizurnab Data from FIRE-3 trial.
    Berger, Martin D.
    Stintzing, Sebastian
    Yang, Dongyun
    Cao, Shu
    Miyamoto, Yuji
    Suenaga, Mitsukuni
    Soni, Shivani
    Gopez, Roel
    Melendez, Elizabeth
    Zhang, Wu
    Heinemann, Volker
    Lenz, Heinz-Josef
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [7] Genetic variants in R-Spondin/RNF43 complex and gene expression levels to predict efficacy of cetuximab (cet) in patients (pts) with metastatic colorectal cancer (mCRC): Data from the FIRE-3 phase III trial
    Battaglin, Francesca
    Xiao, Yi
    Millstein, Joshua
    Seeber, Andreas
    Arai, Hiroyuki
    Wang, Jingyuan
    Puccini, Alberto
    Tokunaga, Ryuma
    Naseem, Madiha
    Soni, Shivani
    Berger, Martin D.
    Barzi, Afsaneh
    Zhang, Wu
    Stintzing, Sebastian
    Heinemann, Volker
    Lenz, Heinz-Josef
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [8] Genetic variant of TWEAK to predict clinical outcome in mCRC patients (pts) treated with first line FOLFIRI and Bevacizumab (FOLFIRI/BEV) in FIRE-3 and TRIBE cohorts
    Parekh, Anish
    Ning, Yan
    Stintzing, Sebastian
    Loupakis, Fotios
    Zhang, Wu
    Yang, Dongyun
    Sunakawa, Yu
    Stremitzer, Stefan
    Matsusaka, Satoshi
    Okazaki, Satoshi
    Elkhoueiry, Rita
    Mendez, Angela
    Barzi, Afsaneh
    Schirripa, Marta
    Heinemann, Volker
    Lenz, Heinz-Josef
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [9] BRCA1 genetic variant to predict survival in metastatic colorectal cancer (mCRC) patients (pts) treated with FOLFIRI/bevacizumab (bev): Results from phase III TRIBE and FIRE-3 trials.
    Naseem, Madiha
    Cao, Shu
    Stintzing, Sebastian
    Loupakis, Fotios
    Berger, Martin D.
    Puccini, Alberto
    Tokunaga, Ryuma
    Battaglin, Francesca
    Barzi, Afsaneh
    Soni, Shivani
    Millstein, Joshua
    Salem, Mohamed E.
    Cremolini, Chiara
    Zhang, Wu
    Heinemann, Volker
    Falcone, Alfredo
    Lenz, Heinz-Josef
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [10] Somatic Alterations and Tumor Mutational Burden (TMB) in Patients with Metastatic Colorectal Cancer (mCRC) Treated with FOLFiRI Plus Bevacizumab or Cetuximab (Fire-3 Trial)
    Stahler, Arndt
    Stintzing, Sebastian
    von Einem, Jobst C.
    Westphalen, C. Benedikt
    Kraemer, Nicole
    Michl, Marlies
    Modest, Dominik Paul
    von Weikersthal, Ludwig Fischer
    Decker, Thomas
    Kiani, Alexander
    Heintges, Tobias
    Kahl, Christoph
    Kullmann, Frank
    Scheithauer, Werner
    Moehler, Markus
    Vehling-Kaiser, Ursula
    Kirchner, Thomas
    Jung, Andreas
    Heinemann, Volker
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 48 - 48
12345